Citations 1225

P2–348: MRI, MRS and clinical correlates in posterior cortical atrophy and typical Alzheimer's disease

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_11 | Pages: No page available

10.1016/j.jalz.2006.05.1188

P2–299: FMRI activation patterns during encoding and recognition in normal elderly and amnestic mild cognitive impairment patients

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_11 | Pages: No page available

10.1016/j.jalz.2006.05.1138

P2–255: Do atrophy rates accelerate in MCI and normal aging?

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_10 | Pages: No page available

10.1016/j.jalz.2006.05.1094

P2–254: Imaging biomarkers to monitor treatment effects for Alzheimer's disease trials: The Alzheimer's disease imaging initiative

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_10 | Pages: No page available

10.1016/j.jalz.2006.05.1093

P2–198: Patterns of decreased glucose metabolism differ among younger and older mild cognitive impairment patients; an FDG PET study

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_10 | Pages: No page available

10.1016/j.jalz.2006.05.1036

P2–193: Progression of cognitive impairments in mild cognitive impairment: What is the next domain to be impaired after memory?

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_10 | Pages: No page available

10.1016/j.jalz.2006.05.1031

P2–190: The prevalence of neuropsychiatric symptoms in normal aging and mild cognitive impairment: A population–based study

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_10 | Pages: No page available

10.1016/j.jalz.2006.05.1028

P2–186: Treatment of mild cognitive impairment with vitamin E and donepezil: Correlations between serial MRI and conversion, genotype, and treatment status

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_10 | Pages: No page available

10.1016/j.jalz.2006.05.1024

P2–171: Clinical predictors of progression to Alzheimer's disease in amnestic mild cognitive impairment

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_10 | Pages: No page available

10.1016/j.jalz.2006.05.1009

Mild Cognitive Impairment Should Be Considered for DSM-V

Journal of Geriatric Psychiatry and Neurology | August 1, 2006 | Volume: 19 | Issue: 3 | Pages: 147-154

10.1177/0891988706291085 | PMID 16880356

Mild cognitive impairment is a topic of great activity from both clinical and research perspectives. It represents a transitional state between the cognitive changes of aging and the earliest clinical manifestations of dementia. We present a case for its inclusion in the Diagnostic and Statistical Manual of Mental Disorders (5th ed; DSM-V) based on clinical, outcome, epidemiological, neuroimaging, and pathophysiological data. The strongest case for inclusion can be made for the amnestic subtype, which is likely a clinical precursor of Alzheimer’s disease. Arguments are presented as to why mild cognitive impairment can be considered as an entity distinct from normal aging and from clinically probable Alzheimer’s disease and why it deserves consideration as a separate construct. In many respects, mild cognitive impairment fulfills criteria for inclusion more adequately than many other conditions currently codified in DSM-IV. Future research directions to help clarify some of the remaining uncertainties are proposed.